Intravenous tissue plasminogen activator for acute ischemic stroke in patients with renal dysfunction.
暂无分享,去创建一个
F. Sung | C. Hsu | T. Yen | W. Chang | S. Hsu | T. Lai | L. Lien | Y. Sun | I-Kuan Wang | P. Huang | C. -. Chen | P. -. Chen | C. -. Chen | C. -. Lin | Y. Su | M. Lin | C. -. Li | Y. Su
[1] J. Jeng,et al. Renal dysfunction increases the risk of recurrent stroke in patients with acute ischemic stroke. , 2018, Atherosclerosis.
[2] J. Jeng,et al. Renal function is associated with 1-month and 1-year mortality in patients with ischemic stroke. , 2017, Atherosclerosis.
[3] M. Woodward,et al. Influence of Renal Impairment on Outcome for Thrombolysis-Treated Acute Ischemic Stroke: ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study) Post Hoc Analysis , 2017, Stroke.
[4] Eric E. Smith,et al. Renal Dysfunction Is Associated With Poststroke Discharge Disposition and In-Hospital Mortality: Findings From Get With The Guidelines–Stroke , 2017, Stroke.
[5] Sung-Chun Tang,et al. Low estimated glomerular filtration rate is associated with poor outcomes in patients who suffered a large artery atherosclerosis stroke. , 2015, Atherosclerosis.
[6] Ming Liu,et al. Renal Dysfunction and Thrombolytic Therapy in Patients With Acute Ischemic Stroke , 2014, Medicine.
[7] Eric E. Smith,et al. Chronic Kidney Disease and Bleeding Complications After Intravenous Thrombolytic Therapy for Acute Ischemic Stroke , 2014, Circulation. Cardiovascular quality and outcomes.
[8] H. Chiou,et al. Stroke: Morbidity, Risk Factors, and Care in Taiwan , 2014, Journal of stroke.
[9] Jean-Paul Cristol,et al. Calibration and precision of serum creatinine and plasma cystatin C measurement: impact on the estimation of glomerular filtration rate , 2014, Journal of Nephrology.
[10] D. Leys,et al. IV thrombolysis and renal function , 2013, Neurology.
[11] M. Endres,et al. Severe Renal Impairment Is Associated With Symptomatic Intracerebral Hemorrhage After Thrombolysis for Ischemic Stroke , 2013, Stroke.
[12] M. Kamouchi. Stroke features and management in patients with chronic kidney disease. , 2013, Contributions to nephrology.
[13] Christina B. Ventura,et al. Recent trends in performance and current state of creatinine assays. , 2013, Archives of pathology & laboratory medicine.
[14] R. Bathula,et al. Renal Impairment Reduces the Efficacy of Thrombolytic Therapy in Acute Ischemic Stroke , 2013, Cerebrovascular Diseases.
[15] Michael T. Mullen,et al. Systematic Review of Outcome After Ischemic Stroke Due to Anterior Circulation Occlusion Treated With Intravenous, Intra-Arterial, or Combined Intravenous+Intra-Arterial Thrombolysis , 2012, Stroke.
[16] Jeffrey L Saver,et al. Stroke Declines From Third to Fourth Leading Cause of Death in the United States: Historical Perspective and Challenges Ahead , 2011, Stroke.
[17] K. Kario,et al. Reduced Estimated Glomerular Filtration Rate Is Associated with Stroke Outcome after Intravenous rt-PA: The Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA Registry , 2010, Cerebrovascular Diseases.
[18] J. Jeng,et al. Get With The Guidelines-Stroke Performance Indicators: Surveillance of Stroke Care in the Taiwan Stroke Registry: Get With The Guidelines-Stroke in Taiwan , 2010, Circulation.
[19] C. Schmid,et al. A new equation to estimate glomerular filtration rate. , 2009, Annals of internal medicine.
[20] G. Remuzzi,et al. Treatment of Bleeding in Dialysis Patients , 2009, Seminars in dialysis.
[21] F. Hatz,et al. Renal function and outcome among stroke patients treated with IV thrombolysis , 2008, Neurology.
[22] George L. Adams,et al. Risks and benefits of antiplatelet therapy in uremic patients. , 2008, Advances in chronic kidney disease.
[23] Keith C. Norris,et al. CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. , 2008, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] Charles E McCulloch,et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. , 2004, The New England journal of medicine.
[25] G. Albers,et al. ATLANTIS Trial: Results for Patients Treated Within 3 Hours of Stroke Onset , 2002, Stroke.
[26] M. Kaste,et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II) , 1998, The Lancet.
[27] Koroshetz Wj,et al. Tissue plasminogen activator for acute ischemic stroke. , 1996, The New England journal of medicine.
[28] Joseph P. Broderick,et al. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. , 1995 .